It has been recommended for approval by the EMA’s human medicines committee – the CHMP – as a once-daily maintenance treatment for patients whose asthma can’t be controlled with two-drug ...

QVM149 is a triple therapy consisting of indacaterol (acetate), glycopyrronium (bromide) and mometasone (furoate), which is being developed as a daily inhaled treatment for asthma delivered via ...

Rockville, MD, Jan. 29, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global triple combination therapy market reached a valuation of ...